These initial results will, naturally, make investors more skeptical than they already are, yet as mentioned, the odds of success are presumably higher in non-carrier AD patients.

FORBES: Pfizer And J&J Alzheimer's Drug Fails Late-Stage Trial

After all, just ahead was a presumably closely contested U.S. election, then the fiscal cliff and the debt ceiling, ad nauseam.

FORBES: You Just Missed A Huge Bull Market